Publication:
COPD Clinical Control: predictors and long-term follow-up of the CHAIN cohort.

dc.contributor.authorCalle Rubio, Myriam
dc.contributor.authorRodriguez Hermosa, Juan Luis
dc.contributor.authorde Torres, Juan P
dc.contributor.authorMarin, Jose Maria
dc.contributor.authorMartinez-Gonzalez, Cristina
dc.contributor.authorFuster, Antonia
dc.contributor.authorCosio, Borja G
dc.contributor.authorPeces-Barba, German
dc.contributor.authorSolanes, Ingrid
dc.contributor.authorFeu-Collado, Nuria
dc.contributor.authorLopez-Campos, Jose Luis
dc.contributor.authorCasanova, Ciro
dc.contributor.groupCHAIN Study Investigators
dc.date.accessioned2023-02-09T10:41:10Z
dc.date.available2023-02-09T10:41:10Z
dc.date.issued2021-01-21
dc.description.abstractControl in COPD is a dynamic concept that can reflect changes in patients' clinical status that may have prognostic implications, but there is no information about changes in control status and its long-term consequences. We classified 798 patients with COPD from the CHAIN cohort as controlled/uncontrolled at baseline and over 5 years. We describe the changes in control status in patients over long-term follow-up and analyze the factors that were associated with longitudinal control patterns and related survival using the Cox hazard analysis. 134 patients (16.8%) were considered persistently controlled, 248 (31.1%) persistently uncontrolled and 416 (52.1%) changed control status during follow-up. The variables significantly associated with persistent control were not requiring triple therapy at baseline and having a better quality of life. Annual changes in outcomes (health status, psychological status, airflow limitation) did not differ in patients, regardless of clinical control status. All-cause mortality was lower in persistently controlled patients (5.5% versus 19.1%, p = 0.001). The hazard ratio for all-cause mortality was 2.274 (95% CI 1.394-3.708; p = 0.001). Regarding pharmacological treatment, triple inhaled therapy was the most common option in persistently uncontrolled patients (72.2%). Patients with persistent disease control more frequently used bronchodilators for monotherapy (53%) at recruitment, although by the end of the follow-up period, 20% had scaled up their treatment, with triple therapy being the most frequent therapeutic pattern. The evaluation of COPD control status provides relevant prognostic information on survival. There is important variability in clinical control status and only a small proportion of the patients had persistently good control. Changes in the treatment pattern may be relevant in the longitudinal pattern of COPD clinical control. Further studies in other populations should validate our results.
dc.description.versionSi
dc.identifier.citationCalle Rubio M, Rodriguez Hermosa JL, de Torres JP, Marín JM, Martínez-González C, Fuster A, et al. COPD Clinical Control: predictors and long-term follow-up of the CHAIN cohort. Respir Res. 2021 Feb 4;22(1):36
dc.identifier.doi10.1186/s12931-021-01633-y
dc.identifier.essn1465-993X
dc.identifier.pmcPMC7863480
dc.identifier.pmid33541356
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7863480/pdf
dc.identifier.unpaywallURLhttps://doi.org/10.1186/s12931-021-01633-y
dc.identifier.urihttp://hdl.handle.net/10668/17108
dc.issue.number1
dc.journal.titleRespiratory research
dc.journal.titleabbreviationRespir Res
dc.language.isoen
dc.organizationHospital Universitario Reina Sofía
dc.organizationInstituto Maimónides de Investigación Biomédica de Córdoba-IMIBIC
dc.organizationInstituto de Biomedicina de Sevilla-IBIS
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number12
dc.publisherBioMed Central
dc.pubmedtypeClinical Trial
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.pubmedtypeObservational Study
dc.relation.publisherversionhttps://respiratory-research.biomedcentral.com/articles/10.1186/s12931-021-01633-y
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectChronic obstructive pulmonary disease
dc.subjectControl
dc.subjectManagement
dc.subject.decsBroncodilatadores
dc.subject.decsEnfermedad pulmonar obstructiva crónica
dc.subject.decsEspaña
dc.subject.decsEstudios de seguimiento
dc.subject.decsPersona de mediana edad
dc.subject.decsValor predictivo de las pruebas
dc.subject.meshAged
dc.subject.meshBronchodilator agents
dc.subject.meshCohort studies
dc.subject.meshFemale
dc.subject.meshFollow-up studies
dc.subject.meshHumans
dc.subject.meshLongitudinal studies
dc.subject.meshMale
dc.subject.meshMiddle aged
dc.subject.meshPredictive value of tests
dc.subject.meshProspective studies
dc.subject.meshPulmonary disease, chronic obstructive
dc.subject.meshSpain
dc.titleCOPD Clinical Control: predictors and long-term follow-up of the CHAIN cohort.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number22
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC7863480.pdf
Size:
1.38 MB
Format:
Adobe Portable Document Format